Tevogen Bio Holdings Inc.
TVGN
$0.9922
-$0.0178-1.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 574.26% | 133.81% | 288.05% | 790.91% | -39.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 365.99% | 161.74% | 293.64% | 1,169.92% | -34.96% |
| Operating Income | -365.99% | -161.74% | -293.64% | -1,169.92% | 34.96% |
| Income Before Tax | -160.02% | -50.68% | 56.44% | 136.63% | 36.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -160.02% | -50.68% | 56.44% | 136.63% | 36.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -160.02% | -50.68% | 56.44% | 136.63% | 36.57% |
| EBIT | -365.99% | -161.74% | -293.64% | -1,169.92% | 34.96% |
| EBITDA | -374.39% | -164.52% | -299.05% | -1,190.27% | 35.21% |
| EPS Basic | 39.88% | -6.77% | 78.69% | 129.85% | 36.58% |
| Normalized Basic EPS | 5.95% | -57.66% | -203.88% | -894.12% | 30.17% |
| EPS Diluted | 39.88% | -6.77% | 78.37% | 129.85% | 36.58% |
| Normalized Diluted EPS | 5.95% | -57.66% | -203.88% | -894.12% | 30.17% |
| Average Basic Shares Outstanding | 331.03% | 41.81% | 28.47% | 14.44% | -0.03% |
| Average Diluted Shares Outstanding | 331.03% | 41.81% | 28.47% | 14.44% | -0.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |